未登录

M

Michael Bogart

rutgers university new brunswick

H指数:13

被引数:607

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost

BMJ OPEN RESPIRATORY RESEARCH

IF3.4

2024-06-111

OAAI

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

JOURNAL OF ASTHMA AND ALLERGY

IF3

2023-12-016

OAAI

Impact of Mepolizumab on Exacerbations in the US Medicare Population

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2023-02-012

OAAI

Profiling Disease and Economic Burden in CRSwNP Using Machine Learning

JOURNAL OF ASTHMA AND ALLERGY

IF3

2022-09-012

OAAI

Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study

RESPIRATORY MEDICINE

IF3.1

2022-06-0134

OAAI

Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in Asthma

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2022-02-0113

OAAI

Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis

美泊利单抗对危及生命的哮喘患者的现实影响: 美国保险索赔数据库分析

CLINICAL THERAPEUTICS

IF3.6

2021-12-016

PREAI

COPD EXACERBATIONS IN PATIENTS SWITCHED FROM MULTIPLE-INHALER TRIPLE THERAPY TO FF/UMEC/VI

IF8.6

2021-10-011

PRE

CHANGES IN ORAL CORTICOSTEROIDS UTILIZATION IN PATIENTS WITH COPD FOLLOWING INITIATION OF FF/UMEC/VI

IF8.6

2021-10-011

PRE

BURDEN OF SYSTEMIC CORTICOSTEROID UTILIZATION IN COPD

IF8.6

2021-10-011

OA

MEPOLIZUMAB REDUCES EXACERBATIONS, OCS AND COST AMONG PATIENTS WITH SEVERE ASTHMA AND THE HIGHEST EXPENDITURES PRIOR TO TREATMENT

IF8.6

2021-10-011

PRE

CROSS-SECTIONAL SURVEY TO ASSESS THE BURDEN OF NOCTURNAL SYMPTOMS IN PATIENTS WITH COPD

IF8.6

2020-10-010

OAAI

IMPACT OF MEPOLIZUMAB IN PATIENTS WITH LIFE-THREATENING ASTHMA

IF8.6

2020-10-011

OAAI

COPD IS ASSOCIATED WITH AN INCREASED RISK OF HERPES ZOSTER: A RETROSPECTIVE ANALYSIS OF A UNITED STATES CLAIMS DATABASE FROM 2013-2018

IF8.6

2020-10-012

OAAI

CROSS-SECTIONAL SURVEY TO ASSESS COPD MEDICATION USE BY UNITED STATES PHYSICIANS

IF8.6

2020-10-010

OAAI

REASONS WHY PATIENTS WITH SEVERE ASTHMA DISCONTINUE BIOLOGIC TREATMENT

IF8.6

2020-10-010

PREAI

REAL-WORLD ADHERENCE TO SINGLE-INHALER VS MULTIPLE-INHALER TRIPLE THERAPY AMONG PATIENTS WITH COPD IN A COMMERCIALLY INSURED US POPULATION

IF8.6

2020-10-0111

OAAI

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

美泊利单抗在重症哮喘患者中的实际疗效: 对急性发作和费用的检查

JOURNAL OF ASTHMA AND ALLERGY

IF3

2020-01-0149

OAAI

THREE METHODS FOR DEFINING ASTHMA EXACERBATIONS IN REAL-WORLD DATA

VALUE IN HEALTH

IF6

2019-05-010

OAAI

Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting

RESPIRATORY MEDICINE

IF3.1

2018-12-0120

OAAI